EP Patent

EP3730142A1 — Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction

Assigned to AstraZeneca AB · Expires 2020-10-28 · 6y expired

What this patent protects

The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.

USPTO Abstract

The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.

Drugs covered by this patent

Patent Metadata

Patent number
EP3730142A1
Jurisdiction
EP
Classification
—
Expires
2020-10-28
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.